Børresen-Dale AL - Search Results

1

Enhanced detection of mutations in BRCA1 exon 11 using restriction endonuclease fingerprinting-single-strand conformation polymorphism.

Jugessur A, Frost P, Andersen TI, Steine S, Lindblom A, Børresen-Dale AL, Eiken HG. Jugessur A, et al. J Mol Med (Berl). 2000;78(10):580-7. doi: 10.1007/s001090000147. J Mol Med (Berl). 2000. PMID: 11199332

2

Loss of heterozygosity at 11q23.1 in breast carcinomas: indication for involvement of a gene distal and close to ATM.

Laake K, Odegård A, Andersen TI, Bukholm IK, Kåresen R, Nesland JM, Ottestad L, Shiloh Y, Børresen-Dale AL. Laake K, et al. Genes Chromosomes Cancer. 1997 Mar;18(3):175-80. Genes Chromosomes Cancer. 1997. PMID: 9071570

3

Screening of 229 family cancer patients for a germline estrogen receptor gene (ESR) base mutation.

Zelada-Hedman M, Børresen-Dale AL, Lindblom A. Zelada-Hedman M, et al. Hum Mutat. 1997;9(3):289. doi: 10.1002/(SICI)1098-1004(1997)9:3<289::AID-HUMU15>3.0.CO;2-Z. Hum Mutat. 1997. PMID: 9090537 No abstract available.

4

Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families.

Zelada-Hedman M, Børresen-Dale AL, Claro A, Chen J, Skoog L, Lindblom A. Zelada-Hedman M, et al. Br J Cancer. 1997;75(8):1201-4. doi: 10.1038/bjc.1997.205. Br J Cancer. 1997. PMID: 9099970 Free PMC article.

5

A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region.

Zelada-Hedman M, Wasteson Arver B, Claro A, Chen J, Werelius B, Kok H, Sandelin K, Håkansson S, Andersen TI, Borg A, Børresen Dale AL, Lindblom A. Zelada-Hedman M, et al. Cancer Res. 1997 Jun 15;57(12):2474-7. Cancer Res. 1997. PMID: 9192828

6

Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening.

Andersen TI, Eiken HG, Couch F, Kaada G, Skrede M, Johnsen H, Aloysius TA, Tveit KM, Tranebjaerg L, Dørum A, Møller P, Weber BL, Børresen-Dale AL. Andersen TI, et al. Hum Mutat. 1998;11(2):166-74. doi: 10.1002/(SICI)1098-1004(1998)11:2<166::AID-HUMU10>3.0.CO;2-X. Hum Mutat. 1998. PMID: 9482581

7

Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters.

Phelan CM, Borg A, Cuny M, Crichton DN, Baldersson T, Andersen TI, Caligo MA, Lidereau R, Lindblom A, Seitz S, Kelsell D, Hamann U, Rio P, Thorlacius S, Papp J, Olah E, Ponder B, Bignon YJ, Scherneck S, Barkardottir R, Borresen-Dale AL, Eyfjörd J, Theillet C, Thompson AM, Larsson C, et al. Phelan CM, et al. Cancer Res. 1998 Mar 1;58(5):1004-12. Cancer Res. 1998. PMID: 9500463

8

A rare CYP19 (aromatase) variant may increase the risk of breast cancer.

Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P, Børresen-Dale AL. Kristensen VN, et al. Pharmacogenetics. 1998 Feb;8(1):43-8. doi: 10.1097/00008571-199802000-00006. Pharmacogenetics. 1998. PMID: 9511180

9

High-throughput screening for known mutations by automated analysis of single sequencing reactions.

Kristensen T, Kristensen VN, Børresen-Dale AL. Kristensen T, et al. Biotechniques. 1998 May;24(5):832-5. doi: 10.2144/98245dt04. Biotechniques. 1998. PMID: 9591134 Free article.

10

Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases.

Sørlie T, Andersen TI, Bukholm I, Børresen-Dale AL. Sørlie T, et al. Breast Cancer Res Treat. 1998 Apr;48(3):259-64. doi: 10.1023/a:1005953519972. Breast Cancer Res Treat. 1998. PMID: 9598872

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

507 results

Search Page